Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants

Patient

Volumn 10, Issue 2, 2017, Pages 163-185

  Pandya, Ekta Y ^a   Bajorek, Beata ^a,b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CINAHL; COCHRANE LIBRARY; DIET; DRUG ALCOHOL INTERACTION; DRUG MONITORING; EMBASE; EXPECTATION; HEALTH CARE; HUMAN; MEDICATION COMPLIANCE; MEDLINE; MEMORY; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SCISEARCH; SOCIAL STATUS; SYSTEMATIC REVIEW; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; WARFARIN;

EID: 84979223190     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-016-0180-1     Document Type: Review

References (105)

1. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106. doi:10.1001/archinte.165.10.1095.
2. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229–35.
3. Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm. 2004;61(12):1258–64.
4. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.
5. Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013;132(2):e124–30.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Medi. 2011;365(11):981–92.
9. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11(1):8.
10. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013(1):464–70.
11. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, ACC/AHA Task Force Members, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am College Cardiol. 2014;130(23):2071–104.
12. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.
13. Haynes RB, Devereaux P, Guyatt GH. Physicians’ and patients’ choices in evidence based practice: evidence does not make decisions, people do. BMJ. 2002;324(7350):1350.
14. Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.
15. Klaus K. Content analysis: an introduction to its methodology. Thousand Oaks: Sage Publications; 1980.
16. Kim JH, Kim GS, Kim EJ, Park S, Chung N, Chu SH. Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin. J Cardiovasc Nurs. 2011;26(6):466–74.
17. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632–6.
18. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853–60.
19. Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med. 2010;17(1):33–42.
20. Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801–8.
21. Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med. 2005;20(12):1114–9.
22. Kääriäinen M, Paukama M, Kyngäs H. Adherence with health regimens of patients on warfarin therapy. J Clin Nurs. 2013;22(1–2):89–96.
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
24. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331–42.
25. Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–17.
26. Gehlbach SH. Interpreting the medical literature. 3rd ed. New York: McGraw-Hill, Health Professions Division; 1993.
27. Hutchison B. Critical appraisal of review articles. Can Fam Physician. 1993;39:1097–102.
28. Day R. How to write and publish a scientific paper, 5th ed. Phoenix: Oryx; 1998.
29. Thomas J, Harden A, Newman M. Synthesis: combining results systematically and appropriately. In: Gough D, Oliver S, Thomas J, editors. An introduction to systematic reviews. London: Sage Publications Ltd; 2012. p. 179–227.
30. Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. J Dev Effect. 2012;4(3):409–29.
31. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient’s point of view. Thromb Haemost. 2000;83(1):49–53.
32. Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):467–74.
33. Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ. Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med. 2007;18(3):202–8. doi:10.1016/j.ejim.2006.11.005.
34. Tan K, Tallon E, Noone I, Hughes G, O’Shea D, Crowe M. Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med. 2012;3(2):78–81.
35. Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, et al. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151(10):1944–9.
36. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997;103(1):11–7.
37. Ansell JE, Maynard GA, Varga EA, Friedman RJ, Brownstein AP. Survey of atrial fibrillation patients demonstrates gaps in awareness of stroke risk and perceived barriers associated with anticoagulation therapy. Am J Hematol. 2012;87:S157–8.
38. Almeida Gde Q, Noblat Lde A, Passos LC, do Nascimento HF. Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes. 2011;9:91. doi:10.1186/1477-7525-9-91.
39. Zamorano JL, Greiner W, Sandberg A, Oberdiek AM, Bakhai A. Patient preference for chronic treatment for stroke prevention: results from the EUropean Patient Survey in Atrial Fibrillation (EUPS-AF). 2012. http://www.pharmastar.it/pharmastar/binary_files/allegati/FA_Indagine_europea_46201.pdf. Accessed 31 May 2016.
40. Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med. 2013;8(3):237–43.
41. Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation–semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11. doi:10.1093/ageing/afh202.
42. Gebler-Hughes ES, Kemp L, Bond MJ. Patients’ perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy. Ther Adv Drug Saf. 2014;5(6):220–8.
43. Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22(9):1254–9.
44. Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AMS, Berto P, et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013;13:108. doi:10.1186/1471-2261-13-108.
45. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
46. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–72.
47. Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.
48. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2011;106(5):868–76.
49. Elewa HF, DeRemer CE, Keller K, Gujral J, Joshua TV. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis. 2014;38(1):115–20. doi:10.1007/s11239-013-0976-y.
50. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.
51. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
52. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Granada). 2009;7(2):113–23.
53. Vaughan Sarrazin MS, Cram P, Mazur A, Ward M, Reisinger HS. Patient perspectives of dabigatran: analysis of online discussion forums. Patient. 2014;7(1):47–54. doi:10.1007/s40271-013-0027-y.
54. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549–61. doi:10.5414/cp201812.
55. Dabigatran (Pradaxa) for preventing blood clots after hip or knee replacement surgery. Medicine Update-Asking the right questions about new medicines. https://www.nps.org.au/__data/assets/pdf_file/0020/86114/NPS_Medicine_Update_Dabigatran.pdf. Accessed 31 May 2016.
56. Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J. 2014;44(3):261–5. doi:10.1111/imj.12370.
57. Jacobs A, Linn D, Sipe B, Heyerly A, Bokhart G. Evaluation of reasons for dabigatran discontinuation in a community hospital and anticoagulation clinic. Hosp Pharm. 2014;49(2):115–6. doi:10.1310/hpj4902-115.
58. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–9.
59. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.
60. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326–43.
61. Prescribing guidelines for dabigatran, rivaroxaban and apixaban-Western Australian Therapeutic Advisory Group. 21 November 2013. http://scghed.com/wp-content/uploads/2014/01/WATAG-NOAC-Guidelines.pdf. Accessed 31 May 2016.
62. Annals of Long-Term Care. Rivaroxaban reversal agent safe and effective, trial finds: a potential universal antidote for factor Xa inhibitors? 2015 Mar 17. http://spring2015.sawc.net/content/rivaroxaban-reversal-agent-safe-and-effective-trial-finds-potential-universal-antidote. Accessed 31 May 2016.
63. ® (dabigatran etexilate). 2015 Oct 19. https://www.boehringer-ingelheim.com/press-release/fda-approves-praxbind-idarucizumab-specific-reversal-agent-pradaxa-dabigatran. Accessed 31 May 2016.
64. Green D. Antidote to dabigatran is approved. NEJM Journal Watch. 2015 Oct 22. http://www.jwatch.org/na39428/2015/10/22/antidote-dabigatran-approved. Accessed 31 May 2016.
65. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. Am Heart J. 2014;167(6):810–7.
66. Living with new oral anticoagulants (NOACs)-Government of Western Australia Department of Health 2013. http://ww2.health.wa.gov.au/~/media/Files/Corporate/general%20documents/Quality/PDF/Living-with-a-NOAC-2013.ashx. Accessed 31 May 2016.
67. Brighton T. New oral anticoagulant drugs–mechanisms of action. Aust Prescr. 2010;33(2):38–41.
68. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.
69. Spinler SA, Willey VJ. A patient’s guide to taking dabigatran etexilate. Circulation. 2011;124(8):e209–11.
70. Cios D, Fanikos J. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation. 2012;125(14):e542–4.
71. Living safely with rivaroxaban. 2014 Feb 13. http://www.anticoagulation.com.au/Rivaroxaban/Livingsafelywithrivaroxaban/tabid/231/Default.aspx. Accessed 7 Aug 2015.
72. European Medicines Agency. Pradaxa. EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf. Accessed 31 May 2016.
73. Hong C, Kim S, Curnew G, Schulman S, Pullenayegum E, Holbrook A. Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol. 2013;20(3):e229–37.
74. Sjölander M, Eriksson M, Glader E-L. The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open. 2013;3(9):e003551.
75. Elliott RA. Appropriate use of dose administration aids. Aust Prescr. 2014;37:46–50.
76. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme: the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110(3):354–8.
77. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy the West Birmingham atrial fibrillation project. Stroke. 2002;33(1):238–42.
78. Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005;21(7):1085–90. doi:10.1185/030079905X50624.
79. Palacio AM. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence. 2015;9:133–8.
80. Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best–best discrete choice experiment. Pharmacoeconomics. 2014;32(11):1115–27.
81. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.
82. Nessel C, Mahaffey K, Piccini J, Pan G, Patel M, Becker R, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF Trial [abstract]. Chest. 2012;142(4_MeetingAbstracts):84A-A.
83. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723.
84. Lin YP, Tan TY. Do NOACs improve antithrombotic therapy in secondary stroke prevention in nonvalvular atrial fibrillation? Medicine (Baltimore). 2015;94(38):e1627. doi:10.1097/md.0000000000001627.
85. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.
86. Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12(5):626–33.
87. LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62. doi:10.1177/1753944712464101.
88. Sánchez E, Vidán MT, Serra JA, Fernández-Avilés F, Bueno H. Prevalence of geriatric syndromes and impact on clinical and functional outcomes in older patients with acute cardiac diseases. Heart. 2011;97(19):1602–6.
89. Thacker EL, McKnight B, Psaty BM, Longstreth WT Jr, Sitlani CM, Dublin S, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81(2):119–25. doi:10.1212/WNL.0b013e31829a33d1.
90. Gibson J, Coupe J, Watkins C. Medication adherence post-stroke: an exploratory study of stroke unit nurses’ perspectives of potential problems affecting patients early after discharge. Int J Stroke. 2014;9(Suppl. 4):7.
91. Choi JC, Dibonaventura MD, Kopenhafer L, Nelson WW. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence. 2014;8:167–77. doi:10.2147/ppa.s56187.
92. Attaya S, Bornstein T, Ronquillo N, Volgman R, Braun LT, Trohman R, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther. 2012;19(6):432–5.
93. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461–9. doi:10.1185/03007995.2014.933577.
94. The Pharmaceutical Benefit Scheme. Australian Government Department of Health. http://www.pbs.gov.au/medicine/item/2769R. Accessed 31 May 2016.
95. The Pharmaceutical Benefit Scheme. Australian Government Department of Health. http://www.pbs.gov.au/medicine/item/2160Q-2268J-2691P-9465E-9466F-9467G-9468H-9469J. Accessed 31 May 2016.
96. The Pharmaceutical Benefit Scheme. Australian Government Department of Health. http://www.pbs.gov.au/medicine/item/10414d-2735y-2744k-5054b-5061j-5500l. Accessed 31 May 2016.
97. The Pharmaceutical Benefit Scheme. Australian Government Department of Health. http://www.pbs.gov.au/info/about-the-pbs. Accessed 21 June 2016.
98. Protheroe J, Fahey T, Montgomery AA, Peters TJ. Effects of patients’ preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. West J Med. 2001;174(5):311.
99. Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ, et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care. 2007;16(3):216–23. doi:10.1136/qshc.2006.018481.
100. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: medicines to help reduce your risk of a stroke—what are the options? London: NICE; 2014.
101. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation where we are and where we should be going. Circulation. 2014;129(6):704–10.
102. Robinson A, Thomson R. The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. Qual Health Care. 2000;9(4):238–44.
103. Howitt AJ. Anticoagulation therapy for atrial fibrillation: Explaining patients' choices. Cardiovas rev r. 2000;21(10):527–31.
104. Michel J, Mundell D, Boga T, Sasse A. Dabigatran for anticoagulation in atrial fibrillation–early clinical experience in a hospital population and comparison to trial data. Heart, Lung Circ. 2013;22(1):50–5.
105. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN‐RANGE study. Pharmacoepidemiol drug saf. 2008;17(9):853-60.